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It is controversial whether mutation in the melancortin-3 receptor (MC3R) gene is a cause for monogenic obesity in humans. Three novel
mutations in theMC3R, A293T, I335S, and X361S, were identified from morbidly obese subjects. We investigated whether these mutations caused
loss-of-function and the molecular defects if any. Ligand binding, signaling, and cell surface expression of the mutant MC3Rs were studied. I335S
resulted in a complete loss of ligand binding and signaling due to intracellular retention. A293T and X361S MC3Rs had normal ligand binding and
signaling as wild type MC3R. Co-expression studies showed that the mutants did not affect wild type MC3R signaling. Hence the I335S variant
previously identified from obese patients is not expressed at the cell surface when expressed in vitro, suggesting that it might contribute to obesity in
carriers of this variant. Whether A293T and X361S cause obesity remains to be investigated. Additional mutations at I335 showed that I335, part of
the highly conserved N/DPxxY motif, was critical for multiple aspects of the MC3R function, including cell surface expression, ligand binding, and
signaling.
© 2007 Elsevier B.V. All rights reserved.Keywords: Melanocortin-3 receptor; Mutation; Obesity; G protein-coupled receptor; Trafficking1. Introduction
Two neural melanocortin receptors (MCRs), the melanocor-
tin-3 and -4 receptors (MC3R andMC4R), have been cloned [1–
3]. These receptors are G protein-coupled receptors (GPCRs)
that couple primarily to the stimulatory heterotrimeric GTP-
binding protein Gs. Therefore, ligand binding to these receptors
results in increased cAMP level in the cell.
Mouse genetic studies revealed non-redundant roles of these
twoMCRs in energy homeostasis. Whereas the MC4R regulates
food intake as well as energy expenditure, the MC3R does not
affect food intake [4–6]. Through mechanism(s) still not com-
pletely understood, the MC3R regulates feeding efficiency and
fat deposition. Mice lacking both MC3R and MC4R have
exacerbated obesity compared with MC3R or MC4R single
gene knockout mice, again suggesting that the MC3R and⁎ Tel.: +1 334 844 5396; fax: +1 334 844 5388.
E-mail address: taoyaxi@vetmed.auburn.edu.
0925-4439/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2007.09.002MC4R serve non-redundant roles in energy homeostasis [5].
The two original knockout studies were done in C57BL/6J mice,
a mouse line prone to obesity [5,6]. A recent study showed that
in a mouse strain that is responsive to leptin and resistant to
obesity (Black Swiss;129), MC3R knockout mice had a
comparable degree of increased adiposity as the MC4R
knockout mice [7], emphasizing the importance of MC3R in
energy homeostasis.
Earlier human genetic studies did not identify any mutations
inMC3R from patients with obesity and Type 2 diabetes mellitus
[8–11] despite strong linkage of the loci encompassing MC3R
on chromosome 20q.13 with these traits [12–16]. In 2002, a
potential mutation (I183N) was reported from two obese patients
[17]. Functional analysis showed that this mutation indeed
resulted in loss-of-function [18–20]. We showed that this
mutation, which changed a highly conserved Ile/Val at the end of
transmembrane domain (TM) 3, resulted in a defect in G protein-
coupling/activation. The mutant receptor bound to the ligand
(therefore it was expressed on the cell surface) but could not
convey this binding to increased cAMP generation [18]. These
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are strongly supportive of a role of the MC3R in regulating
energy homeostasis in humans; a defect in this regulation results
in obesity. However, I183N was the only mutation reported.
Recently, DiBlasio and her colleagues screened 110 unrelated
morbidly obese subjects with a mean body mass index (BMI) of
47.2 kg/m2 [21]. Another selection criteria for these subjects was
that they had resting energy expenditure/food intake ratios of
greater than 0.7, indicating that they were obese despite burning
more than 70% of their food intake [21]. Three novel MC3R
variants, A293T, I335S, and X361S, were identified. Subjects
harboring A293T or I335S variants had increased fat mass and
decreased lean mass. Their leptin levels were lower than
expected for their BMI. The subject with the X361S variant, a
22 years old woman with a BMI of 44.3 kg/m2, had a very high
amount of fat mass (53.8%) and high serum leptin levels [21].
Family studies with two variants showed co-segregation of the
variant with obesity: heterozygotes for the variants were all
obese. In addition, these three genetic variants were not found in
100 normal weight subjects [21]. However, the functional
properties of these variants were unknown. We sought to
characterize the functional properties of these variants in vitro.
2. Materials and methods
2.1. Hormones and supplies
[Nle4,D-Phe7]-α-MSH (NDP-MSH) was purchased from Bachem (King of
Prussia, PA). Iodinated NDP-MSH was purchased from the Peptide Radio-
iodination Service Center at the University of Mississippi (University, MS).
Tissue culture plastic wares were purchased from Corning (Corning, NY). Cell
culture media, newborn calf serum, and other reagents for cell culture were
obtained from Invitrogen (Carlsbad, CA).
2.2. In vitro mutagenesis of the MC3R
The wild type (WT) MC3R tagged at the N-terminus with 3xHA tag was
obtained from UMR cDNA Resource Center (www.cDNA.org). Mutations were
introduced into WT MC3R by QuikChange™ site-directed mutagenesis kit
(Stratagene, La Jolla, CA) as detailed before [22]. The primers used for
generating the naturally occurring mutants are listed in Table 1. For the X361S
mutant, the original stop codon was replaced by AGC (coding for serine)
followed by GATGCAGGGCCATGGAAA (coding for DAGPWK) followed by
the new stop codon. The nucleotide sequence used for coding DAGPWKwas the
same as in the genomic sequence of the human MC3R. Qiagen Maxiprep kit
(Qiagen, Valencia, CA) was used to prepare the plasmids for transfection.
Automated DNA sequencing was used to confirm that only the intended
mutations were introduced in the constructs.Table 1
Primers used to construct the naturally occurring MC3R mutants





The nucleotides introducing the mutations are highlighted in bold. For the
mutant X361S, the original stop codon was replaced by AGC coding for serine
(highlighted in both bold and italic), followed by nucleotides coding for
DAGPWK as found in the genomic sequence (highlighted in bold) and the new
stop codon (in italic).2.3. Cells and transfections
HEK293 cells, obtained from American Type Culture Collection (Manassas,
VA), were maintained at 5% CO2 in Dulbecco's modified Eagle's medium
containing 50 μg/ml gentamicin, 10 mM HEPES, and 10% newborn calf serum.
Cells were plated on gelatin-coated 35 mm 6-well clusters. When the cells reached
50–70% confluency, they were transfected using the calcium precipitation method
[23]. Four μg plasmid in 2 ml media was used per 35 mm dish. Cells were used
approximately 48 h after transfection for measuring ligand binding and signaling.
In co-expression studies, 2 μg plasmid of WT and mutant were co-transfected,
whereas 2 μg empty vector was added to theWT group so that all groups received
the same amount of DNA.
2.4. Ligand binding to intact cells
The methods for ligand binding were described in detail before [22]. Briefly,
48 h after transfection, cells were washed twice with warm Waymouth/BSA
(Waymouth's MB752/1 media containing 1 mg/ml bovine serum albumin
(BSA)) (herein referred as Waymouth/BSA) and incubated with 100,000 cpm of
125I-NDP-MSHwith or without different concentrations of unlabeled NDP-MSH
(from 10−12 to 10−6 M) at 37 C for 1 h. Cells were then placed directly on ice,
washed twice with cold Hank's balanced salt solution containing 1 mg/ml BSA
and 50 μg/ml gentamicin. Then 100 μl of 0.5 N NaOH was added to each well.
Cell lysates were then collected using cotton swabs, and counted in gamma
counter. Binding capacity and IC50 values were calculated using GraphPad Prism
4.0 software (San Diego, CA).
2.5. Ligand stimulation of intracellular cAMP production
HEK293 cells were plated and transfected as described above. Approxi-
mately 48 h after transfection, cells were washed twice with warm Waymouth/
BSA. Then 1 ml of fresh Waymouth/BSA containing 0.5 mM isobutylmethyl-
xanthine (Sigma) was added to each well. After 15 min incubation at 37 C, either
buffer alone or different concentrations of NDP-MSH were added and the
incubation was continued for another hour. The cells were then placed on ice,
media were aspirated, and intracellular cAMP was extracted by the addition of
0.5 N percholoric acid containing 180 μg/ml theophylline, and measured using
radioimmunoassay. All determinations were performed in triplicate. Iodinated
cAMP was prepared using chloramine T method. Maximal responses (Rmax) and
EC50 values were calculated using Prism 4.0 software.
2.6. Localization of MC3R expression by confocal microscopy
HEK293 cells plated onto poly-D-lysine-coated slides (Biocoat cellware from
Falcon) were transiently transfected with WT or mutant MC3Rs tagged at the N
terminus with three tandem HA epitope tags and immunostained with fluorescein-
conjugated anti-HA antibody. For immunohistochemistry, all solutions and
procedures were at room temperature. On the day of the experiment, cells were
washed three times with filtered phosphate buffered saline for immunohistochem-
istry (PBS-IH, 137 mMNaCl, 2.7 mMKCl, 1.4 mMKH2PO4, 4.3 mMNa2HPO4,
pH 7.4). Cells were then fixed with 4% paraformaldehyde in PBS-IH for 30 min.
After a further wash of three times with PBS-IH, cells were permeabilized with 1%
Triton X-100 in PBS-IH for 5 min. For cell surface staining, this step was omitted.
Then the cells were incubated with blocking solution (5% BSA in PBS-IH) for 1 h,
and incubated 1 h with fluorescein-conjugated anti-HA.11 antibody (Covance,
Berkeley, CA) diluted 1:100 in PBS-IH containing 1 mg/ml BSA. Cells were then
washed 5 times with PBS-IH and covered with Vectashield Mounting Media
(Vector Laboratories) and a glass coverslip. Images were collected with a Zeiss
LSM510 laser scanning confocalmicroscopewith excitation by 488 nmargon laser
and detected with a 530- to 560-nm filter.
2.7. Statistical analyses
Student's t test was used to determine the significance of differences in the
signaling and binding parameters between wt and mutant MC3Rs. The statistical
analysis was carried out using GraphPad Prism 4.0.
Table 2
Ligand binding and agonist-stimulated cAMP production of WT and mutant
MC3Rs










WT 10 6.83±2.55 100 0.67±0.17 100
A293T 5 7.18±1.26 98±10 1.02±0.47 89±12
I335S 5 ND ND ND ND
X361S 5 6.35±3.37 104±8 2.43±1.09 98±22
WT + A293T 4 4.11±1.05 106±9 0.88±0.39 98±22
WT + I335S 4 2.18±0.06⁎⁎ 90±5 0.51±0.09 69±14
WT + X361S 4 3.76±2.06 94±10 0.46±0.22 85±24
I335A 4 ND ND ND ND
I335D 4 ND ND ND ND
I335L 4 0.58±0.10⁎⁎⁎ 4±1⁎⁎⁎ 0.57±0.22⁎⁎⁎ 4±1⁎⁎⁎
I335N 4 ND ND ND ND
I335R 4 ND ND ND ND
I335V 4 2.94±0.92 100±6 0.43±0.05 44±9⁎⁎
Data shown are the mean±SEM of the indicated number of experiments. The
Bmax of cells expressing WT MC3R was 0.047±0.012 nmol NDP-MSH bound/
106 cells and the Rmax was 1328.0±174.5 pmol cAMP/10
6 cells (mean±SEM of
10 experiments).
ND: not detectable.
⁎⁎: pb0.01 compared with WT MC3R.
⁎⁎⁎: pb0.001 compared with WT MC3R.
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Recently, three novel MC3R variants were identified from
morbidly obese patients in Italy: A293T in TM6, I335S in
TM7, and X361S [21]. X361S changed the stop codon to Ser
resulting in the addition of seven amino acids before the
downstream stop codon, so the C terminus starting with the
original stop codon is: 361SDAGPWK. However, the functional
properties of these mutants were unknown. In this study, we
sought to determine whether these mutations resulted in loss-
of-function and what were the functional defects. NDP-MSH, a
superpotent agonist of α-MSH [24], was used for ligand
binding and signaling studies.
3.1. Signaling properties of the mutant receptors
First, we tested whether the three MC3R variants could
respond to NDP-MSH stimulation with increased cAMP gen-
eration. As shown in Fig. 1A, I335S MC3R was totally devoid
of signaling in response to NDP-MSH stimulation. A293T and
X361S signaled relatively normally to NDP-MSH stimulation
with similar Rmax as WT MC3R. The EC50 for A293T was
similar to WT MC3R, whereas that of the X361S was slightly
increased (Table 2). In contrast to the MC4R, the WT MC3R
had no constitutive activity. The basal cAMP levels in cells
transfected with WT MC3R were similar to the basal cAMP
levels in cells transfected with empty vector pcDNA3. The
MC3R variants did not cause any change in constitutive activity
compared to WT MC3R (data not shown).
3.2. Ligand binding properties of the mutant receptors
To investigate whether the mutant MC3Rs had normal bind-
ing to the ligands, we performed competitive binding using
125I-NDP-MSH as the iodinated ligand and cold NDP-MSH
as the competitor. Fig. 1B showed results from a typical ex-Fig. 1. Accumulation of intracellular cAMP and competitive binding of iodinated N
HEK293 cells were transiently transfected withWTor mutant MC3Rs, stimulated wit
with RIA. Results are expressed as mean±SEM of triplicate determinations within on
obtained. Panel B: HEK293 cells were transiently transfected with WT or mutant M
methods. Different concentrations of unlabeled NDP-MSH were used to inhibit the b
range of duplicate determinations within one experiment. All experiments were perfperiment. I335S did not have any specific binding to NDP-MSH,
whereas A293T and X351S had similar binding capacities and
IC50s as the WT MC3R (Table 2).
3.3. Localization of I335S MC3R by confocal microscopy
To investigate whether I335S was defective in ligand binding
per se or was defective in trafficking to plasma membrane, we
performed confocal laser scanning microscopy studies using
MC3Rs tagged at the N-terminus with 3 tandem HA epitopeDP-MSH in cells transiently transfected with WT and mutant MC3Rs. Panel A:
h different concentrations of NDP-MSH, and intracellular cAMP levels measured
e experiment. All experiments were performed five times and similar results were
C3Rs and ligand binding assays were performed as described in Materials and
inding of 125I-NDP-MSH to WT and mutant MC3Rs. Results shown are mean±
ormed five times and similar results were obtained.
Fig. 2. Confocal imaging of WT and mutant MC3Rs. HEK293 cells expressing WT and mutant MC3Rs were permeabilized or left intact as indicated and then stained
with fluorescein-conjugated anti-HAmonoclonal antibody and imaged by confocal microscopy. Panels are: A,WT; B: I335S; C, I335A; D, I335D; E, I335L; F, I335N;
G, I335R; H, I335V.
Fig. 3. Accumulation of intracellular cAMP and agonist binding in cells expressing WT and/or mutant MC3Rs. HEK293 cells were transiently transfected with the
indicated MC3R constructs, and intracellular cAMP accumulation and binding assays were performed. The same amount of WT MC3R plasmid was present in all
groups. Empty vector was added to keep plasmid concentrations constant among the different groups. Panel A: HEK293 cells transiently transfected with the MC3R
constructs were stimulated with various concentrations of NDP-MSH and intracellular cAMP levels were measured. Results are expressed as the mean±SEM of
triplicate determinations within one experiment. All experiments were performed four times and similar results were obtained. Panel B: HEK293 cells transiently
transfected with the MC3R constructs were used to measure ligand-binding properties. Different concentrations of unlabeled NDP-MSH were used to displace the
binding of [125I]-NDP-MSH to WT or mutant MC3Rs on intact cells. Results shown are expressed as the mean±range of duplicate determinations within one
experiment. All experiments were performed four times and similar results were obtained.
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Fig. 4. Multiple mutagenesis of I335. I335 was mutated to Ala, Asn, Asp, Arg, Leu, Val, and tested for their signaling (A) and ligand binding (B) properties. Panel A:
HEK293 cells transiently transfected with WT or mutant MC3Rs were stimulated with different concentrations of NDP-MSH. Intracellular cAMP levels were
measured with RIA. Results are expressed as mean±SEM of triplicate determinations within one experiment. The experiments were performed four times and similar
results were obtained. Panel B: HEK293 cells were transiently transfected with WT or mutant MC3Rs and ligand binding assays were performed. Different
concentrations of unlabeled NDP-MSH were used to compete the binding of 125I-NDP-MSH to WT and mutant MC3Rs. Results shown are mean±range of duplicate
determinations within one experiment. All experiments were performed four times and similar results were obtained. There were no signaling or ligand binding for
I335A, I335N, I335D, and I335R (data not shown).
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tag did not affect ligand binding or signaling significantly (data
not shown). Cells transiently transfected with WT or I335S
MC3Rs were stained with fluorescein-conjugated anti-HA
antibody and visualized under a confocal microscope. As
shown in Fig. 2, WTMC3R was expressed on the cell surface as
well as intracellularly. I335S was devoid of cell surface staining,
whereas permeabilization revealed intracellular staining (Fig. 2)
suggesting that the mutant receptor was expressed but retained
intracellularly.
3.4. Co-expression of WT and mutant MC3Rs
To investigate whether the mutant MC3Rs had any dominant
negative activity on WT MC3R, co-expression experiments
were performed. Cells were co-transfected with WT and mutant
MC3Rs. Empty vector was used so that all groups had the same
amount of plasmids transfected. The results of these experi-
ments showed that the mutant MC3Rs had no dominant
negative activity on the WT MC3R signaling or binding (Fig.
3A and B and Table 1). In fact, cells co-transfected with I335S
had significantly decreased IC50 (increased binding affinity)
(Table 2).
3.5. Multiple mutagenesis of I335 revealed its critical
importance in MC3R function
Isoleucine at codon 335 belongs to the highly conserved
N/DPxxY motif (Asn/Asp–Pro–Xaa–Xaa–Tyr) in TM7. In the
MC3R, it is DPLIY. To gain further insight into the importance
of I335 in cell surface expression of the MC3R, we generated
multiple mutants that changed I335 to hydrophobic (Ala, Leu,
and Val), polar (Asn), or charged (Asp and Arg) residues. The
results of these experiments showed that mutants I335A, I335D,I335N, and I335R did not exhibit any binding to 125NDP-MSH
or signaling in response to NDP-MSH stimulation (Table 2 and
data not shown). I335L retained minimal although discernible
binding and signaling. I335V had similar binding properties as
WT MC3R; however, the maximal response decreased by half
(Fig. 4 and Table 2). The EC50s for I335L and I335V were
similar to that of the WT MC3R (Table 2).
Confocal microscopy experiments showed that mutants that
changed Ile into charged residues (I335D and I335R) were
expressed but totally retained intracellularly. The other
mutants, including I335A, I335N, I335L, and I335V, could
be detected in non-permeabilized cells, suggesting that they
were expressed on the cell surface (Fig. 2). These results
suggested that I335 was important in MC3R function. When
mutated, it could result in intracellular retention or defects in
ligand binding and signaling depending on the amino acids
introduced.
4. Discussion
In this study, we characterized three novel naturally
occurring MC3R variants recently identified from morbidly
obese subjects [21]. We showed that I335S was totally devoid
of ligand binding and signaling due to intracellular retention
(Figs. 1, 2), suggesting that I335S might contribute to obesity
in the patients harboring the variant allele. Previous studies in
other GPCRs have shown that intracellular retention is the most
common defect of naturally occurring mutations in GPCRs that
cause human diseases (reviewed in [22,25,26]). Especially
relevant is that intracellular retention is the most common
defect in MC4R mutations associated with obesity [22,27–29].
Recently, Beaumont and colleagues showed that some of the
melanocortin-1 receptor mutations associated with pigmenta-
tion defects also had reduced cell surface expression [30].
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had reduced total protein level. However, the localization of the
receptor was not altered [31]. The two novel variants identified
in Singaporean patients (A70T and M134I) were reported to
have defects in signaling [20].
The other two MC3R variants, A293T and X361S, did not
cause major defects in cell surface expression, ligand binding
and signaling (Fig. 1 and Table 2). When co-expressed with WT
MC3R, they also did not affect WT MC3R signaling (Fig. 3).
Whether these two mutants were the cause of morbid obesity
observed in the patients remain unknown. In addition, the clin-
ical and genetic data on the identification of these mutations are
eagerly awaited in peer-reviewed literature.
Although it is well established that mutations in the MC4R
is the most common monogenic form of obesity, it is
controversial whether mutations in the MC3R can also cause
human obesity. Previously, several large scale screening studies
did not identify any mutations in the MC3R [8–11]. Only a
single potential mutation was identified in the MC3R from two
patients (father and daughter) in Singapore [17]. We and others
showed that the mutant receptor I183N was defective in
signaling [18–20]. We showed that whereas the mutant receptor
bound to the ligand normally, it could not convey the ligand
binding to increased Gs activation as measured by increased
intracellular cAMP level. In co-transfection experiments, the
mutant receptor did not affect WT MC3R binding or signaling
[18]. Therefore these results would suggest that I183N might
cause obesity due to haploinsufficiency rather than dominant
negative activity, similar to the MC4R [32]. Lee and colleagues
recently confirmed these results [20]. However, a study by
Rached and coworkers showed that I183N MC3R was retained
intracellularly and had dominant negative activity on WT
MC3R [19]. Regardless of the exact cause of loss-of-function,
all three studies showed that I183N resulted in loss of signaling
in response to NDP-MSH stimulation, consistent with the
hypothesis that the mutation might be the cause of increased
adiposity in the patients. Recently, Feng et al. showed that the
polymorphic variant T6K/V81I is associated with obesity in
African Americans [31]. Very recently, two other mutations
were identified from obese children [20]. Together with the
results presented here for I335S, these studies suggested that
MC3R mutations might be relevant in human adiposity. Further
studies using genetically targeted animals that express the
mutant MC3Rs, preferably in mouse strains that are resistant to
obesity (such as Black Swiss;129) [7], are needed to confirm
these in vitro studies.
With the MC4R, some of the naturally occurring mutations
identified from obese patients do not cause defective signaling
in vitro [22,25,33–35]. Whether these mutations were respon-
sible for the obesity observed is not known. Similarly, in the
present study, we showed that the two variants A293T and
X361S did not exhibit major deleterious effect. It should be
pointed out that the present experiments were done in cultured
cells. Minor defect may have escaped detection by the methods
used here. In addition, these variants might have defects in other
aspects of receptor function such as desensitization and inter-
nalization or other signaling pathways.Previously we suggested a classification scheme to
catalogue the naturally occurring mutations in the MC4R
gene associated with obesity [22]. In this scheme, Class I
mutants are not expressed; Class II mutants are retained intra-
cellularly; Class III mutants are expressed on the cell surface
but defective in ligand binding; Class IV mutants can bind to
the ligands but are defective in signaling; Class V mutations
have no known defects [22]. According to this scheme, I335S
belongs to Class II, whereas A293T and X361S belong to
Class V.
The dramatic effect of I335S variant, together with the fact
that I335 resides in the signature motif N/DPxxY (in the MC3R,
it is DPLIY), prompted us to investigate further the role of I335
in MC3R function. Previous structure–function studies concen-
trated on the highly conserved Asn, Pro and Tyr (see [36–38] for
examples). The two residues that are not conserved were not
studied in detail. This isoleucine I335 is fully conserved in all the
melanocortin receptors cloned so far (GPCR database at www.
gpcr.org/7tm, version 10.0, released in June 2006). Therefore we
performed additional mutagenesis studies on I335. Our studies
showed that mutations of I335 into charged residues such as
Asp and Arg resulted in intracellular retention, likely due to
misfolding. Mutants I335A, I335L, I335N, and I335V had
similar localization as the WT MC3R (Fig. 2). However, I335A
and I335N did not bind to NDP-MSH, I335L exhibited minimal
binding and signaling, I335V bound to NDP-MSH normally but
had decreasedmaximal response (Fig. 4). These results highlight
the importance of I335 in multiple aspects of receptor function,
including cell surface expression, ligand binding, and signaling.
Since I335 is located at the end of TM7, I335 might interact with
hydrophobic residues in helix 8 to maintain the conformation
necessary for normal trafficking, ligand binding and signaling.
Valine might be able to partially interact with those residues
therefore only demonstrated a decreased signaling. The other
residues might result in more severe defect in forming these
interactions. Further studies are needed to identify these in-
tramolecular interactions.
Of all the inactivating mutations in GPCRs that cause
human diseases, premature termination resulting in a truncated
receptor is not uncommon. However, there are few examples of
mutations that change the stop codon to a coding sequence
resulting in a mutant receptor longer than the WT receptor.
Previously a mutation in rhodopsin was found to change the
stop codon to Gln resulting in 51 additional amino acids being
added before the downstream stop codon [39]. The functional
consequence of this mutation is not known. However, the fact
that it was associated with very severe retinitis pigmentosa
suggested that it might result in a significant functional defect.
Another example is the GPR54, where a mutation that changes
the stop codon to Arg extending the open reading frame all the
way to the polyA signal. This mutation is associated with
idiopathic hypogonadotropic hypogonadism [40]. The mutant
receptor had decreased second messenger production [40]. We
showed here that X361S MC3R did not cause major functional
defects.
In summary, we provided evidences that were consistent
with I335S as a possible genetic contributor for morbid obesity.
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pression, ligand binding, and signaling.
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